Page URL:

Gene therapy and drug studies show promise for treatment of cystic fibrosis

26 July 2009
Appeared in BioNews 518

Scientists have used two new techniques to fix defects in lung cells from people with cystic fibrosis, raising hope for new treatments for the disease in the future. The first study, published in the journal Plos Biology, used a gene therapy technique to treat the cells, whilst the second study, published in the American Journal of Respiratory Cell and Molecular Biology, used a drug called miglustat.

Cystic fibrosis is an inherited genetic disorder that affects more than 8000 children and young adults in the UK. It affects individuals who carry two faulty copies of a gene called cystic fibrosis transmembrane regulator (CFTR), and results in mucus throughout the body becoming thicker and stickier than usual. This prevents several organs, in particular the lungs and digestive system, from functioning properly, and makes sufferers very susceptible to infections which can often be incurable or life-threatening. There are currently no cures or treatments that target the cause of the disease, although symptoms can be alleviated.

In the first study, researchers at the University of North Carolina at Chapel Hill School of Medicine used a genetically-engineered parainfluenza virus (which is one of the viruses that causes common colds) to deliver normal, fully functional CFTR genes to lung cells from individuals with cystic fibrosis that were being grown in a dish to create a model of airway tissue. Using this technique, the researchers were able to correct the CFTR gene in 60 to 70 per cent of cells, and these cells produced normal mucus secretions. Importantly, they found that they only needed to deliver the corrected CFTR gene to 25 per cent of cells for normal function to be restored to the model airway tissue.

Professor Ray Pickles, who led the study, said: 'we discovered that if you take a virus that has evolved to infect the human airways, and you engineer a normal CFTR gene into it, you can use this virus to correct all of the hallmark cystic fibrosis features in the model system that we used'. The technique could not yet be used in humans, as the virus delivery system would first need to be rigorously tested for safety, but hope remains for the future.

In the second study, researchers at the Université de Poitiers, France, treated lung cells carrying mutations in the CTFR gene with low doses of miglustat, a drug currently approved for the treatment of rare metabolic disorders. They found that after three to four days, CFTR activity was restored to normal, and could be maintained thereafter. The results of this study have prompted the drug's manufacturer, Actelion Pharmaceuticals, Switzerland, to perform further investigations and to reconsider their earlier decision to halt clinical trials for the use of miglustat to treat cystic fibrosis sufferers.

Common Cold Virus Efficiently Delivers Corrected Gene To Cystic Fibrosis Cells
Science Daily |  20 July 2009
Treatment Of Cystic Fibrosis: Encouraging New Results For Miglustat
Science Daily |  22 July 2009
30 July 2012 - by Dr Rosie Morley 
The European Medicines Agency has recommended European Union market approval for a gene therapy, Glybera, to treat patients with severe cases of a rare genetic condition called lipoprotein lipase deficiency...
19 March 2012 - by Heidi Colleran 
The largest trial for a gene therapy for cystic fibrosis (CF) will begin in the UK this month. Coordinated by the UK Cystic Fibrosis Gene Therapy Consortium (GTC), 130 patients will be recruited and given working copies of the defective gene that leads to their condition...
22 November 2010 - by Dr Lux Fatimathas 
American researchers have successfully treated cystic fibrosis patients with a new drug targeting the cause of the disease. Patients carrying a common genetic mutation associated with cystic fibrosis were treated with the drug VX-770...
23 February 2009 - by Rosie Beauchamp 
The results of a study carried out at the University of California, Berkeley and the University of Iowa, US have reported significant development in the field of gene therapy. Published this week in the online journal Proceedings of the National Academy of Sciences, the research documents the...
9 June 2005 - by BioNews 
The inherited lung disorder cystic fibrosis (CF) could be treated using parts of two viruses to deliver a therapeutic gene, US researchers say. A team based at the University of Pennsylvania says that it has successfully used a 'hybrid' of the viruses that cause HIV and Ebola to deliver test...
26 April 1999 - by BioNews 
The possibility of a genetic treatment for cystic fibrosis has moved a step closer with the start of a gene therapy trial at Stanford University Medical Center in California. The treatment involves the delivery, by aerosol, to the patient's lungs of a manufactured version of the cystic fibrosis transmembrane conductance...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.